Year All2024202320222021202020192018201720162015201420132012201120102007 04.04.17 Syndax Pharmaceuticals Adds Biopharmaceutical Industry Leader Keith A. Katkin to Board of Directors WALTHAM, Mass., April 04, 2017 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq:SNDX), a clinical stage biopharmaceutical company focused on developing entinostat and SNDX-6352 in multiple cancer indications, today announced the appointment of Keith A. Read More 03.29.17 Syndax Announces Presentations at the 2017 American Association for Cancer Research Annual Meeting WALTHAM, Mass., March 29, 2017 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq:SNDX), a clinical stage biopharmaceutical company focused on developing entinostat and SNDX-6352 in multiple cancer indications, announces a list of select poster presentations Read More 03.02.17 Syndax Pharmaceuticals Reports Fourth Quarter and Year-end 2016 Financial Results and Provides Clinical and Business Update Encore 601 refractory melanoma cohort to proceed to second stage of Phase 2; pre-specified objective response criteria satisfied Enrollment of the first stage of both NSCLC cohorts completed; decision whether to progress each cohort into the second stage of Phase 2 anticipated in 1H2017 WALTHAM, Read More 02.27.17 Syndax Pharmaceuticals Announces Participation at Three Upcoming Investor Conferences WALTHAM, Mass., Feb. 27, 2017 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals, Inc. (Nasdaq:SNDX), a clinical stage biopharmaceutical company focused on developing entinostat and SNDX-6352 in multiple cancer indications, today announced its planned participation in three upcoming investor conferences. Read More 02.16.17 Syndax to Announce Fourth Quarter and Year-end 2016 Financial Results and Host Conference Call and Webcast on March 2, 2017 WALTHAM, Mass., Feb. 16, 2017 (GLOBE NEWSWIRE) -- Syndax (Nasdaq:SNDX) announced today that it will release its fourth quarter 2016 financial results on Thursday, March 2, 2017, after the close of the U.S. financial markets. In connection with the earnings release, Syndax's management team will Read More 02.09.17 Syndax Appoints Richard P. Shea as Chief Financial Officer WALTHAM, Mass., Feb. 09, 2017 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq:SNDX), a clinical stage biopharmaceutical company focused on developing entinostat and SNDX-6352 in multiple cancer indications, today announced that Richard P. Read More 01.31.17 Syndax Appoints Lisa M. Coussens, Ph.D., to Scientific Advisory Board Adds additional scientific and clinical expertise in critical immune-regulated pathways therapeutically relevant for oncology Read More 01.05.17 Syndax Adds Global Pharmaceutical Business Veteran to Board of Directors WALTHAM, Mass., Jan. 05, 2017 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq:SNDX), a clinical stage biopharmaceutical company focused on developing entinostat and SNDX-6352 in multiple cancer indications, today announced the appointment of Pierre Read More 12.14.16 Syndax Pharmaceuticals Announces Collaboration with the National Cancer Institute to Develop Entinostat and SNDX-6352 for the Treatment of Cancer WALTHAM, Mass., Dec. 14, 2016 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals, Inc. ("Syndax," or "we") (Nasdaq:SNDX), a clinical stage biopharmaceutical company focused on developing entinostat and SNDX-6352 in multiple cancer indications, today announced that it has entered into a Cooperative Research Read More 11.21.16 Syndax Pharmaceuticals to Present at the 28th Annual Piper Jaffray Healthcare Conference WALTHAM, Mass., Nov. 21, 2016 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals, Inc. (Nasdaq:SNDX), a clinical stage biopharmaceutical company focused on developing entinostat and SNDX-6352 in multiple cancer indications, today announced that Chief Executive Officer Briggs W. Read More 11.10.16 Syndax Pharmaceuticals Reports Third Quarter 2016 Financial Results and Provides Business Update Execution on clinical timelines and advancement of oncology programs continues with initiation of: Phase 2 cohorts of ENCORE 601 in NSCLC and melanoma Phase 1 clinical trial of SNDX-6352 WALTHAM, Mass., Nov. 10, 2016 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals, Inc. Read More 11.08.16 Syndax Pharmaceuticals to Present at the SITC 31st Annual Scientific Meeting WALTHAM, Mass., Nov. 08, 2016 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq:SNDX), a clinical stage biopharmaceutical company focused on developing entinostat and SNDX-6352 in multiple cancer indications, today announced six poster presentations at the Read More
04.04.17 Syndax Pharmaceuticals Adds Biopharmaceutical Industry Leader Keith A. Katkin to Board of Directors WALTHAM, Mass., April 04, 2017 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq:SNDX), a clinical stage biopharmaceutical company focused on developing entinostat and SNDX-6352 in multiple cancer indications, today announced the appointment of Keith A. Read More
03.29.17 Syndax Announces Presentations at the 2017 American Association for Cancer Research Annual Meeting WALTHAM, Mass., March 29, 2017 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq:SNDX), a clinical stage biopharmaceutical company focused on developing entinostat and SNDX-6352 in multiple cancer indications, announces a list of select poster presentations Read More
03.02.17 Syndax Pharmaceuticals Reports Fourth Quarter and Year-end 2016 Financial Results and Provides Clinical and Business Update Encore 601 refractory melanoma cohort to proceed to second stage of Phase 2; pre-specified objective response criteria satisfied Enrollment of the first stage of both NSCLC cohorts completed; decision whether to progress each cohort into the second stage of Phase 2 anticipated in 1H2017 WALTHAM, Read More
02.27.17 Syndax Pharmaceuticals Announces Participation at Three Upcoming Investor Conferences WALTHAM, Mass., Feb. 27, 2017 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals, Inc. (Nasdaq:SNDX), a clinical stage biopharmaceutical company focused on developing entinostat and SNDX-6352 in multiple cancer indications, today announced its planned participation in three upcoming investor conferences. Read More
02.16.17 Syndax to Announce Fourth Quarter and Year-end 2016 Financial Results and Host Conference Call and Webcast on March 2, 2017 WALTHAM, Mass., Feb. 16, 2017 (GLOBE NEWSWIRE) -- Syndax (Nasdaq:SNDX) announced today that it will release its fourth quarter 2016 financial results on Thursday, March 2, 2017, after the close of the U.S. financial markets. In connection with the earnings release, Syndax's management team will Read More
02.09.17 Syndax Appoints Richard P. Shea as Chief Financial Officer WALTHAM, Mass., Feb. 09, 2017 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq:SNDX), a clinical stage biopharmaceutical company focused on developing entinostat and SNDX-6352 in multiple cancer indications, today announced that Richard P. Read More
01.31.17 Syndax Appoints Lisa M. Coussens, Ph.D., to Scientific Advisory Board Adds additional scientific and clinical expertise in critical immune-regulated pathways therapeutically relevant for oncology Read More
01.05.17 Syndax Adds Global Pharmaceutical Business Veteran to Board of Directors WALTHAM, Mass., Jan. 05, 2017 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq:SNDX), a clinical stage biopharmaceutical company focused on developing entinostat and SNDX-6352 in multiple cancer indications, today announced the appointment of Pierre Read More
12.14.16 Syndax Pharmaceuticals Announces Collaboration with the National Cancer Institute to Develop Entinostat and SNDX-6352 for the Treatment of Cancer WALTHAM, Mass., Dec. 14, 2016 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals, Inc. ("Syndax," or "we") (Nasdaq:SNDX), a clinical stage biopharmaceutical company focused on developing entinostat and SNDX-6352 in multiple cancer indications, today announced that it has entered into a Cooperative Research Read More
11.21.16 Syndax Pharmaceuticals to Present at the 28th Annual Piper Jaffray Healthcare Conference WALTHAM, Mass., Nov. 21, 2016 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals, Inc. (Nasdaq:SNDX), a clinical stage biopharmaceutical company focused on developing entinostat and SNDX-6352 in multiple cancer indications, today announced that Chief Executive Officer Briggs W. Read More
11.10.16 Syndax Pharmaceuticals Reports Third Quarter 2016 Financial Results and Provides Business Update Execution on clinical timelines and advancement of oncology programs continues with initiation of: Phase 2 cohorts of ENCORE 601 in NSCLC and melanoma Phase 1 clinical trial of SNDX-6352 WALTHAM, Mass., Nov. 10, 2016 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals, Inc. Read More
11.08.16 Syndax Pharmaceuticals to Present at the SITC 31st Annual Scientific Meeting WALTHAM, Mass., Nov. 08, 2016 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq:SNDX), a clinical stage biopharmaceutical company focused on developing entinostat and SNDX-6352 in multiple cancer indications, today announced six poster presentations at the Read More